Company news
Hikma Pharmaceuticals Plc (LSE:HIK) news
Hikma Pharmaceuticals Plc news releases on 6ix. Latest, Sep 24, 2026: Hikma appoints Rebecca Hall as CFO
Press releases & updates
Hikma appoints Rebecca Hall as CFO
September 24, 2026
Hikma R&D Investor Spotlight Series
September 22, 2026
Hikma advances its epinephrine nasal spray with multi-market regulatory filings
September 10, 2026
Hikma Pharmaceuticals : advances its epinephrine nasal spray with multi-market regulatory filings
September 9, 2026
Hikma Pharmaceuticals : advances climate progress with first solar energy agreement
August 11, 2026
Directorate change
August 6, 2026
Hikma Pharmaceuticals : welcomes FDA approval of Guardant360® Liquid CDx
June 22, 2026
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
June 4, 2026
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
June 1, 2026
Hikma Pharmaceuticals : and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) C...
May 5, 2026
Hikma Pharmaceuticals : announces settlement agreement for VYNDAMAX® (tafamidis)
April 28, 2026
Hikma Pharmaceuticals : reiterates full year 2026 guidance following encouraging start to the year
April 23, 2026
Transaction in Own Shares
March 23, 2026
Annual Financial Report and Notice of AGM
March 18, 2026
Director/PDMR Shareholding
March 11, 2026
Total Voting Rights
March 2, 2026
Launch of Buyback Programme
February 26, 2026
Final Results, Share Buyback & Leadership Changes
February 26, 2026
Hikma Pharmaceuticals : launches authorised generic of Nucynta® (tapentadol) in the US
February 25, 2026
Statement regarding Hikma Pharmaceuticals Plc
February 4, 2026
Notice of Results
February 3, 2026
Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables
January 12, 2026
Hikma announces CEO change and Board appointment
December 15, 2025
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
December 8, 2025
Holding(s) in Company
November 11, 2025
November Trading Statement
November 6, 2025
Block listing Interim Review
October 1, 2025
Half-year Report
August 7, 2025
Publication of Offering Circular
July 7, 2025
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
July 2, 2025
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
June 28, 2025
Fitch upgrades Hikma to ‘BBB’
May 29, 2025
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
May 27, 2025
Medium-term Group guidance ahead of US site visit
May 15, 2025
S&P upgrades Hikma to ‘BBB’
May 8, 2025
Settlement agreement for Xyrem® US lawsuits
May 8, 2025
Result of AGM
April 24, 2025
Trading Statement
April 24, 2025
Hikma acquires Novugen's FDA-approved ANDA for trametinib
April 17, 2025
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
March 20, 2025
Final Results
February 26, 2025
Outcome of Audit Tender Process
November 7, 2024
2024 Annual General Meeting Update Statement
October 24, 2024
Hikma completes Xellia acquisition
September 10, 2024
Director Declaration
July 29, 2024
Hikma acquires Xellia’s assets
June 17, 2024
Hikma appoints new President of Generics business
April 15, 2024
Agreement in Principle for US Opioid Settlement
February 1, 2024
Company Secretary Change
December 29, 2023
Hikma appoints new President of Injectables
August 9, 2023